New Product Development Capabilities and the Ongoing Burden of Development Investment
First written in FY2016. 15 of 16 entries say "Restated". Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥55,026 million for the cumulative consolidated period through the third quarter of the current fiscal year.」
Disclosed an investment of ¥5.5026 billion in R&D during the cumulative third quarter of the fiscal year, for R&D investment that continues regardless of earnings. - FY2024-Q2RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥35,609 million for the cumulative consolidated period through the second quarter of the current fiscal year.」
Disclosed an investment of ¥3.5609 billion in R&D during the cumulative second quarter of the fiscal year, for R&D investment that continues regardless of earnings. - FY2024-Q1RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥17,734 million for the cumulative consolidated period through the first quarter of the current fiscal year.」
Disclosed an investment of ¥1.7734 billion in R&D during the cumulative first quarter of the fiscal year, for R&D investment that continues regardless of earnings. - FY2023-Q3RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥49,797 million for the cumulative consolidated period through the third quarter of the current fiscal year.」
Disclosed an investment of ¥4.9797 billion in R&D during the cumulative third quarter of the fiscal year as part of its ongoing R&D investment. - FY2023-Q1RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥15,368 million for the cumulative consolidated period through the first quarter of the current fiscal year.」
Disclosed an investment of ¥1.5368 billion in R&D during the cumulative first quarter of the fiscal year, for R&D investment that continues regardless of earnings. - FY2022-Q3RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥43,301 million for the cumulative consolidated period through the third quarter of the current fiscal year.」
Disclosed an investment of ¥4.3301 billion in R&D during the cumulative third quarter of the fiscal year, for R&D investment that continues regardless of earnings. - FY2022-Q1RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥14,217 million for the cumulative consolidated period through the first quarter of the current fiscal year.」
The company disclosed development investment of ¥14.217 billion during the cumulative first quarter period as part of its ongoing research and development investment regardless of earnings conditions. - FY2021RestatedAnnual report
「Accordingly, the group must continue investing in product development regardless of fluctuations in its earnings.」
The company reaffirmed its recognition that development investment in new products and next-generation technologies must continue regardless of earnings fluctuations. - FY2021-Q3RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥43,614 million for the cumulative consolidated period through the third quarter of the current fiscal year.」
The company disclosed cumulative investment of ¥43.614 billion in ongoing research and development regardless of earnings conditions. - FY2021-Q2RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥29,182 million for the cumulative consolidated period through the second quarter of the current fiscal year.」
The company disclosed cumulative investment of ¥29.182 billion in ongoing research and development regardless of earnings conditions. - FY2020-Q3RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥45,797 million for the cumulative consolidated period through the third quarter of the current fiscal year.」
The company disclosed ¥45.797 billion of investment during the cumulative third quarter period in ongoing research and development. - FY2020-Q1RestatedAnnual report
「R&D investment, including development costs recognized as intangible assets, totaled ¥15,088 million for the cumulative consolidated period through the first quarter of the current fiscal year.」
The company disclosed development investment of ¥15.088 billion during the cumulative first quarter period as part of its ongoing research and development investment regardless of earnings conditions. - FY2018RestatedAnnual report
「The group must continue investing in product development regardless of fluctuations in its earnings.」
The company reiterated its recognition of the risk that ongoing development investment in new products and next-generation technologies is necessary regardless of earnings fluctuations. - FY2018-Q3RestatedAnnual report
「The group's core businesses operate in highly competitive markets and are continually required to develop new products through advanced and ongoing research and development. Accordingly, the group must continue investing in product development regardless of fluctuations in its earnings.」
The company continues to disclose the need to maintain development investment in new products and next-generation technologies regardless of earnings fluctuations, as well as the risk that the results will not translate into earnings. - FY2017RestatedAnnual report
「The group's core businesses operate in highly competitive markets and are continually required to develop new products through advanced and ongoing research and development. Accordingly, the group must continue investing in product development regardless of fluctuations in its earnings.」
The company continues to disclose the need to maintain investment in new product development regardless of earnings fluctuations, as well as the risks of failing to achieve investment results and delays in bringing products to market. - FY2016First statedAnnual report
「The group's core businesses operate in highly competitive markets and are continually required to develop new products through advanced and ongoing research and development. Accordingly, the group must continue investing in product development regardless of fluctuations in its earnings.」
The risks identified for the Precision Equipment, Imaging and Medical businesses include development delays, failure of market acceptance, patent competition and failure to achieve the expected returns on investment.